Fallacies of last observation carried forward analyses

Clinical Trials

Volumn 13, Issue 2, 2016, Pages 161-168

  Lachin, John M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

imputation; Last observation carried forward; missing data

Indexed keywords

ALTERNATIVE HYPOTHESIS; ARTICLE; DATA ANALYSIS; DATA PROCESSING; FOLLOW UP; LAST OBSERVATION CARRIED FORWARD ANALYSIS; NULL HYPOTHESIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL BIAS; STATISTICAL MODEL; VALIDITY; INFORMATION PROCESSING; LONGITUDINAL STUDY; METHODOLOGY;

BIAS (EPIDEMIOLOGY); DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; FOLLOW-UP STUDIES; LONGITUDINAL STUDIES; RESEARCH DESIGN;

EID: 84960449345     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515602688     Document Type: Article

References (13)

1. Little RJ, Rubin DB,. Statistical analysis with missing data. 2nd ed. New York: Wiley, 2002.
2. National Research Council. The prevention and treatment of missing data in clinical trials (Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education). Washington, DC: The National Academies Press, 2010.
3. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355-1360.
4. O'Neill RT, Temple R,. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012; 91: 550-554.
5. Ware JH, Harrington D, Hunter DJ, et al. Missing data. N Engl J Med 2012; 367: 1353-1354.
6. Kenward MG, Molenberghs G,. Last observation carried forward: a crystal ball? J Biopharm Stat 2009; 19: 872-888.
7. Siddiqui O, Ali MW,. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat 1998; 8: 545-563.
8. Veberke G, Molenberghs G, Bijnens L, et al. Linear mixed models in practice. New York: Springer, 1997.
9. Cohen AC,. Estimation in mixtures of two normal distributions. Technometrics 1967; 9: 15-28.
10. Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for industry: diabetes mellitus-developing drugs and therapeutic biologics for treatment and prevention., 2008, http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf (. accessed 4 January 2015).
11. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
12. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
13. Lachin JM,. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000; 21: 167-189.